# Members Obtain Free CE Credits from JCP Articles!

***Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation Combined With Hypertension: A Multicenter, Retrospective Cohort Study***

August 2023 – *The Journal of Clinical Pharmacology* (JCP)

***Why is this article important to you?***
It is unclear whether there are differences in direct oral anticoagulant efficacy and safety in patients with atrial fibrillation (AF) combined with hypertension. Atrial fibrillation is the most common clinically significant cardiac arrhythmia. From 1990 to 2010, the overall global incidence of AF increased by 27.7% and 35.8% in men and women, respectively, and the mortality associated with AF increased by a factor of 2 and 1.9, respectively. Age is one of the main risk factors for AF, with the risk of AF doubling with every 10-year increase in age. In recent years, with the increasing global trend of population aging, the increase in the elderly population will further increase the prevalence and incidence of AF. Atrial fibrillation is associated with an increased risk of stroke and thromboembolism, and AF–related stroke leads to higher mortality. This article provides information about a multicenter retrospective cohort study to assess the differences in the efficacy and safety of direct oral anticoagulants in patients with AF combined with hypertension.

**ACPE Accreditation Statement**
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
**UAN: 0665-0000-23-032-H01-P**– ACPE 1 Contact Hours
**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience**: 'P'

**ACCME Accreditation Statement**
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**ACCME Designation Statement**
The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Target Audience**
Interprofessional team of Physicians, General Clinicians, Pharmacists and PhDs interested in the impact of oral anticoagulants in patients with atrial fibrillation (AF) combined with hypertension.

**Learning Objectives**
After completing this activity, the learner will be able to:

1. Identify major risk factors for atrial fibrillation (AF);
2. Compare the efficacy results of rivaroxaban and dabigatran in patients with AF and hypertension;
3. Describe the safety findings comparing rivaroxaban and dabigatran;
4. Discuss the impact of body mass index (BMI) on rivaroxaban and dabigatran disposition.

**Requirements to Receive Credit**

To receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

**Disclosures:**

Article Selection: Joseph S. Bertino Jr, PharmD, Editor-in-Chief, *The Journal of Clinical Pharmacology*, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Planners: Michael W. Jann, PharmD, Professor, Univ of North Texas System Coll of Pharmacy has no relevant relationship(s) with ineligible companies to disclose.

CE Reviewer: Steven Tung, MD, JD, Anesthesiologist, has no relevant relationship(s) with ineligible companies to disclose.

**Schedule & Fees**
JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

**Acknowledgment of Financial Support**
No financial support was received for this educational activity.

**Home Study Initial Release and Expiration Dates**
**Date of Issuance:** 08/01/2023
**Expiration Date:** 08/01/2026

**Reporting CPE Credits to ACPE Monitor**
Learners seeking CPE credit must also provide ACCP with their National Association of Boards of Pharmacy (NABP) Profile Number and the month and day of their birth via email to CE@ACCP1.org. The NABP Profile Number and birthday information is required for ACCP to transmit CPE credit information via the CPE Monitor.

---

**System Requirements**
For best visual quality, we recommend viewing the Journal CE in the Chrome browser. If you do not have Chrome, you can download it here.

**Helpful Tips**
Download the article and access the Self-assessment Post-test, Evaluation and Certificate here.

Learn how to print your CME/CPE Certificate here.

---